Form 4: Kalaris Director Akkaraju Plans $15M Stock Purchase

Kalaris Therapeutics Director Srinivas Akkaraju, through Samsara Opportunity Fund, L.P., plans to acquire 1.5 million shares of common stock for $15 million on December 22, 2025.

Summary

• Srinivas Akkaraju, a Director and 10% owner of Kalaris Therapeutics, Inc. (KLRS), along with Samsara Opportunity Fund, L.P. and Samsara Opportunity Fund GP, LLC, reported a planned acquisition of common stock.
• The transaction involves the acquisition of 1,500,000 shares of Kalaris Therapeutics common stock.
• The acquisition price is $10 per share, totaling $15,000,000.
• The transaction is scheduled to occur on December 22, 2025.
• This acquisition is being made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.
• Following this transaction, Samsara Opportunity Fund, L.P. will indirectly beneficially own 1,500,000 shares, and Samsara BioCapital, L.P. will indirectly beneficially own 11,448,081 shares.
• Dr. Akkaraju, Samsara Opportunity Fund GP, LLC, and Samsara BioCapital GP, LLC have voting and investment power over these securities.

Sentiment

Score: 8

Explanation: The planned acquisition of a significant block of shares by a director and major shareholder, especially under a 10b5-1 plan, indicates strong long-term confidence in the company's value and future prospects. This is a very positive signal for investors.

Positives

• A significant planned insider purchase of 1.5 million shares at $10 per share, totaling $15 million, signals strong confidence from a director and major shareholder in the company's future prospects.
• The transaction is pre-planned under Rule 10b5-1(c), suggesting a deliberate investment strategy rather than a reaction to immediate market fluctuations.
• Increased insider ownership aligns the interests of management and major shareholders with those of public shareholders.

Negatives

• The transaction date is in the future (December 22, 2025), meaning the immediate impact of the purchase on market sentiment is delayed.

Future Outlook

The planned acquisition in December 2025 suggests a long-term positive outlook from a key insider and major investor, indicating confidence in the company's future performance beyond the immediate term.

Industry Context

Insider buying, especially by a director and significant shareholder, can be a positive signal in the biotechnology sector, where company-specific developments often drive stock performance. It suggests confidence in Kalaris Therapeutics' pipeline or strategic direction.

Comparison to Industry Standards

• This is a specific insider transaction, not a company performance report. Direct comparison to industry-wide financial benchmarks or competitor project results is not applicable. However, insider buying is generally viewed favorably across all industries as a sign of confidence.

Related Party Transactions

• Srinivas Akkaraju, a Director and 10% owner, is involved in the acquisition through entities he controls (Samsara Opportunity Fund, L.P. and Samsara Opportunity Fund GP, LLC).

Stakeholder Impact

• Shareholders: The planned insider purchase could boost investor confidence, potentially leading to increased demand and a positive impact on share price. It signals alignment of interests.
• Company: The transaction reflects strong internal belief in the company's strategy and future, which can positively influence employee morale and external perception.

Next Steps

• The actual execution of the planned stock acquisition on December 22, 2025.

Key Dates

Recommendation

The planned acquisition of 1.5 million shares at $10 per share by a director and 10% owner, totaling $15 million, is a very strong signal of confidence. Such a substantial insider purchase, especially pre-planned under a 10b5-1 plan, suggests that a key insider believes the stock is undervalued or expects significant positive developments. This aligns management's interests with shareholders and typically precedes positive stock performance.

Keywords

Kalaris Therapeutics, KLRS, Srinivas Akkaraju, Insider Buying, Form 4, Stock Acquisition, Samsara BioCapital, 10b5-1 plan, Biotechnology, Director Purchase